Harms From Uninformative Clinical Trials

September 3, 2019, Vol 322, No. 9, Pages 795-900


Harms From Uninformative Clinical Trials
Deborah A. Zarin, MD; Steven N. Goodman, MD, MHS, PhD; Jonathan Kimmelman, PhD
JAMA. 2019;322(9):813-814. doi:10.1001/jama.2019.9892
This Viewpoint discusses key features of and incentives for randomized clinical trials (RCTs) that make many of them uninformative; reviews the challenges uninformative trials pose to ethics, science, and medical practice; and recommends what academic medical centers and funders can do to incentivize the conduct of RCTs that provide valid information that informs clinical practice.